HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.

Abstract
Donor lymphocyte infusion (DLI) can restore durable molecular remission in a high percentage of patients with chronic myeloid leukemia (CML) who have relapses after allogeneic stem cell transplantation, but for patients who do not respond survival is poor. Imatinib mesylate (STI571) is a specific inhibitor of BCR-ABL tyrosine kinase that can induce hematologic and cytogenetic remissions in patients with CML. We report here a male patient who had a relapse to chronic phase after stem cell transplantation for CML, did not benefit from treatment with DLI, and then was administered STI571 at a dose of 400 mg daily. There was a rapid, complete hematologic response, and complete restoration of donor-type hematopoiesis (100% 46, XX marrow metaphases) was achieved after 6 months of therapy, though RT-PCR studies still detected BCR-ABL transcripts in the blood at low level. This case demonstrates that imatinib mesylate can be highly effective in the management of patients who have relapses after allograft for CML.
AuthorsEduardo Olavarria, Charles Craddock, Francesco Dazzi, David Marin, Sarah Marktel, Jane F Apperley, John M Goldman
JournalBlood (Blood) Vol. 99 Issue 10 Pg. 3861-2 (May 15 2002) ISSN: 0006-4971 [Print] United States
PMID11986250 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
Topics
  • Adult
  • Antineoplastic Agents (therapeutic use)
  • Benzamides
  • Cytogenetic Analysis
  • Enzyme Inhibitors (therapeutic use)
  • Fusion Proteins, bcr-abl (antagonists & inhibitors)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, genetics, therapy)
  • Male
  • Neoplasm Recurrence, Local (drug therapy)
  • Piperazines (therapeutic use)
  • Pyrimidines (therapeutic use)
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: